Treatment of Multiple Myeloma
Publication Date: April 1, 2019
Last Updated: December 15, 2022
Treatment
Transplant Eligible
Patients should be referred to a transplant center to determine transplant eligibility. ( EB , H , H , M )
3336
Chronologic age and renal function should not be the sole criteria used to determine eligibility for stem cell transplantation (SCT). ( EB , H , H , M )
3336
The optimal regimen and number of cycles remain unproven. However, at least 3-4 cycles of induction therapy including an immunomodulatory drug, proteasome inhibitor and steroids is advised prior to stem cell collection. ( EB , H , H , M )
3336
Upfront transplant should be offered to all transplant-eligible patients. Delayed initial SCT may be considered in select patients. ( EB , H , B , S )
3336
Agents associated with stem cell toxicity, such as melphalan and/or prolonged immunomodulatory drugs exposure (more than 4 cycles), should be avoided in patients who are potential candidates for SCT. ( EB , H , H , M )
3336
Ample stem cell collection (sufficient for more than one SCT) should be considered upfront, due to concern for limited ability for future stem cell collection after prolonged treatment exposure. ( EB , H , H , M )
3336
The level of minimal response required to proceed to SCT is not established for patients receiving induction therapy – patients should be referred for SCT independent of depth of response. ( EB , H , H , M )
3336
High-dose melphalan is the recommended conditioning regimen for Auto SCT. ( EB , H , B , S )
3336
Tandem autologous SCT should not be routinely recommended. ( EB , L , B , M )
3336
Salvage or delayed SCT may be used as consolidation at first relapse for those not choosing to proceed to transplant initially. ( EB , H , H , M )
3336
Allogeneic transplant for multiple myeloma is not routinely recommended but may be considered in select high risk patients or in the context of a clinical trial. ( EB , H , B , M )
3336
Consolidation therapy is not routinely recommended but may be considered in the context of a clinical trial. For patient’s ineligible or unwilling to consider maintenance therapy, consolidation therapy for at least 2 cycles may be considered. ( EB , H , H , M )
3336
Lenalidomide maintenance therapy should be routinely offered to standard risk patients starting at approximately day 90-110 at 10-15 mg daily until progression. A minimum of 2 years of maintenance therapy is associated with improved survival, and efforts to maintain therapy for at least this duration are recommended. ( EB , H , B , S )
3336
For patients intolerant of or unable to receive lenalidomide, bortezomib maintenance every 2 weeks may be considered. ( IC , H , H , M )
3336
For high-risk patients, maintenance therapy with a proteasome inhibitor +/- lenalidomide may be considered. ( IC , H , H , M )
3336
There is insufficient evidence to make modifications to maintenance therapy based on depth of response, including minimal residual disease (MRD) status. ( IC , H , H , W )
3336
The quality and depth of response should be assessed by IMWG (International Myeloma Working Group) criteria. ( EB , H , B , S )
3336
The goal of initial therapy for transplant eligible patients should be achievement of the best depth of remission. MRD negative status has been associated with improved outcomes, but it should not be used to guide treatment goals outside the context of a clinical trial. ( EB , H , H , S )
3336
It is recommended that depth of response be assessed with each cycle. Frequency of assessment once best response is attained or on maintenance therapy may be assessed less frequently but at minimum every 3 months. ( EB , H , B/H , )
3336
Whole-body low dose CT scan has been shown to be superior to skeletal survey done with plain x-rays and is the preferred method for baseline and routine bone surveillance. FDG-PET/CT and/or MRI may be used as alternatives at baseline. They may also be used in select situations (e.g. risk stratifying smoldering myeloma, for monitoring response of non-secretory and oligosecretory myeloma and if CT or skeletal survey is inconclusive). ( EB , H , H , S )
3336
Transplant Ineligible
Initial treatment recommendations for patients with multiple myeloma who are transplant ineligible should be individualized based on shared decision-making between physicians and patients. Multiple factors should be considered; disease-specific factors such as stage and cytogenetic abnormalities, patient-specific factors including age, comorbidities, functional status, frailty status and patient preferences should also be considered. ( EB , H , B , M )
3336
Initial treatment for patients with multiple myeloma who are transplant ineligible should include at minimum a novel agent (immunomodulatory drug or proteasome inhibitor) and a steroid if possible. ( EB , H , B , S )
3336
Triplet therapies for patients with multiple myeloma who are transplant ineligible, including bortezomib-lenalidomide-dexamethasone should be considered. Daratumumab + bortezomib + melphalan + prednisone may also be considered. ( EB , H , B , S )
3336
Physicians/patients should balance the potential improvement in response and disease control with a possible increase in toxicity. Initial dosing should be individualized based on patient age, renal function, comorbidities, functional status and frailty status. Subsequent dosing may be tailored based on initial response and tolerability. ( EB , H , H , M )
3336
Continuous therapy should be offered over fixed duration therapy when initiating an immunomodulatory drug or proteasome inhibitor-based regimen. ( EB , H , B , S )
3336
The goal of initial therapy for transplant ineligible patients should be achievement of the best quality and depth of remission. ( EB , H , H , M )
3336
Depth of response for all patients should be assessed by IMWG criteria (Table 5) regardless of transplant eligibility. ( EB , H , H , S )
3336
There is insufficient evidence to support change in type and length of therapy based on depth of response as measured by conventional IMWG approaches or MRD. ( IC , I , H , W )
3336
Upon initiation of therapy, one should define patient specific goals of therapy. Quality of life assessment (including symptom management and tolerability of treatment) should be assessed at each visit to determine if the goals of therapy are being maintained/met and this should influence the intensity and duration of treatment. Redefining the goals prospectively, based on response, symptoms and quality of life is recommended. ( IC , H , H , W )
3336
It is recommended that patients be monitored closely with consideration of dose modifications based on levels of toxicity, neutropenia, fever/infection, tolerability of side effects, performance status, liver and kidney function and in keeping with the goals of treatment. ( IC , H , H , W )
3336
Relapsed Disease
Treatment for biochemically relapsed myeloma should be individualized. Factors to consider include patient’s tolerance of prior treatment, rate of rise of myeloma markers, cytogenetic risk, presence of comorbidities (i.e. renal insufficiency), frailty, and patient preference. High-risk patients as defined by high-risk cytogenetics and early relapse post-transplant/initial therapy should be treated immediately. Close observation is appropriate for patients with slowly progressive and asymptomatic relapse. ( IC , H , H , M )
3336
All clinically relapsed patients with symptoms due to myeloma should be treated immediately. ( EB , H , B , S )
3336
Triplet therapy should be administered on first relapse, though the patient’s tolerance for increased toxicity should be considered. A triplet is defined as a regimen with two novel agents (proteasome inhibitors, immunomodulatory drugs or monoclonal antibodies). ( EB , H , B , S )
3336
Treatment of relapsed multiple myeloma may be continued until disease progression. There is not enough data to recommend risk based versus response-based duration of treatment (such as MRD). ( EB , H , H , M )
3336
Prior therapies should be taken into consideration when selecting the treatment at first relapse. A monoclonal antibody-based regimen in combination with an immunomodulatory drugs and/or proteasome inhibitor should be considered. Triplet regimens are preferred based on tolerability and comorbidities. ( EB , H , H , W )
3336
Autologous stem cell transplantation, if not received after primary induction therapy, should be offered to transplant eligible patients with relapsed multiple myeloma. Repeat stem cell transplant may be considered in relapsed multiple myeloma if PFS after first transplant is 18 months or greater. ( EB , H , B/H , W )
3336
The risk status of the patients should be assessed using the Revised ISS staging system for all patients at the time of diagnosis. ( EB , H , B , S )
3336
Repeat risk assessment at the time of relapse should be performed and should include bone marrow with FISH for myeloma abnormalities seen with progression including, 17p and 1q abnormalities. FISH for primary abnormalities (translocations and trisomies), if seen in the initial diagnostic marrow, does not need to be repeated. ( EB , H , B , S )
3336
Assessment of other risk factors such as renal insufficiency, age, presence of plasma cell leukemia, circulating plasma cells, extramedullary disease and frailty, should also be considered/performed. ( EB , H , B , S )
3336
In patients with genetic high-risk disease a triplet combination of proteasome inhibitor, immunomodulatory drug and a steroid should be the initial treatment, followed by one or two autologous SCT, followed by a proteasome inhibitor-based maintenance until progression. ( EB , H , B , S )
3336
In patients with renal insufficiency, drugs should be modified based on renal clearance. ( EB , H , B , S )
3336
In patients with plasma cell leukemia or extra medullary disease, cytotoxic chemotherapy may have a role. ( EB , H , H , M )
3336
The IMWG revised response criteria should be used for response assessment. ( EB , H , B , S )
3336
All measurable parameters need to be followed including light and heavy chain analysis. ( EB , H , B , S )
3336
All responses excluding marrow and imaging should be confirmed as per IMWG criteria. ( EB , H , B , S )
3336
Response assessment should be performed after one cycle of therapy, and once a response trend is observed it may be done every other cycle and less frequently once patient is in a plateau. ( EB , H , B , S )
3336
Recommendation Grading
Disclaimer
Overview
Title
Treatment of Multiple Myeloma
Authoring Organizations
American Society of Clinical Oncology
Cancer Care Ontario
Publication Month/Year
April 1, 2019
Last Updated Month/Year
December 15, 2022
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Target Patient Population
Patients with multiple myeloma
Target Provider Population
Medical oncologists, radiation oncologists, hematologists, surgeons, nurses, advanced practice providers, oncology pharmacists
Inclusion Criteria
Female, Male, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Keywords
multiple myeloma, hematologic malignancies
Source Citation
DOI: 10.1200/JCO.18.02096 Journal of Clinical Oncology 37, no. 14 (May 10, 2019) 1228-1263.